SavedAdd your journal

Journals / Maltepe Tıp Dergisi / 2015 / Cilt: 7 - Sayı: 2

Insulin resistance

İnsülin direnci

Eşref M. ÖZER
Pages
1–5
Publication Date
2015-08-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The syndromes of insulin resistance present a clinical spectrum which includes obesity, glucose intolerance, type 2 diabetes and the metabolic syndrome, as well as an extreme insulin-resistant state.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Insulin resistance is a state in which a given concentration of insulin produces a less-than-expected biological effect.
📊
Key Findings & Data:Insulin resistance is defined as the requirement of high dose insulin to attain glycemic control and to prevent ketosis.
💡
Conclusion & Impact:The syndromes of insulin resistance present a clinical spectrum which includes obesity, glucose intolerance, type 2 diabetes and the metabolic syndrome, as well as an extreme insulin-resistant state.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:insülin direnci · obezite · tip 2 diyabet

Abstract

Insulin resistance is a state in which a given concentration of insulin produces a less-than-expected biological effect. Insulin resistance is defined as the requirement of high dose insulin to attain glycemic control and to prevent ketosis. The syndromes of insulin resistance present a clinical spectrum which includes obesity, glucose intolerance, type 2 diabetes and the metabolic syndrome, as well as an extreme insulin-resistant state.

Özet

İnsülin direnci, insülinin beklenen biyolojik etkisinden daha azını gösterme halidir. İnsülin direnci, glisemik kontrol ve ketozu önlemek için daha yüksek dozlarda insülin konsantrasyonuna ihtiyaç gösterir. İnsülin sendromları, klinikte kendisini obezite, bozulmuş glukoz toleransı, tip 2 diyabet, metabolik sendrom ve ciddi insülin direnci sendromları ile gösterir.

🔖

Cite This Article

ÖZER, E. M. (2015). Insulin resistance. Maltepe Tıp Dergisi, Cilt: 7 - Sayı: 2, 1–5. https://ajindex.com/articles/230913

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ahren B, Pacini G. Islet adaptation to insulin resistance: mechanisms and implications for intervention. Diabetes Obes Metab 2005; 7(1): 2-8.
  2. Mari A, Ahren B, Pacini G. Assessment of in- sulin secretion in relation to insulin resistance. Curr Opin Clin Nutr Metab care 2005; 8(5): 529-533. Reaven GM. Pathophsiology of insulin resist- ance in human disease. Physiol Rev. 1995; 75(3): 473-486.
  3. Kim JA, Wei Y, Sowers JR. Role of mitochon- drial dysfunction in insulin resistance. Circ Res 2008; 102(4): 401-414.
  4. Lee SH, Park SA, Ko SH et al. Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascu- lar disease in type 2 diabetes mellitus patients. Metabolism 2010; 59(2): 241-246.
  5. Klok MD, Jakopsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev. 2007; 8(1): 21-34.
  6. Reaven G, Abbasi F, McLaughin T. Obesity, insulin resistance and cardiovascular disease. Recent Prog Horm Res 2004; 59: 207-223.
  7. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med. 2008; 14(3-4): 222-231.
  8. Florez H, Castillo-Florez S, Mendez A et al. C-reactive protein is elavated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract 2006; 71(1): 92-100. Rifai N. High-sensitivity C-reactive protein: a useful marker for cardiovascular disease risk prediction and the metabolic syndrome. Clin Chem. 2005; 51(3): 504-505.
  9. Semple RK, Cochran EK, Soos MA et al. Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin re- sistance. Diabetes Care. 2008; 31(5): 977-979.
  10. Moreno-Navarrete JM, Catalan V, Ortega F et al. Circulating omentin concentration increases after weight loss. Nutr Metab. 2010; 7: 27-36.
  11. Diamant M, Tushuizen ME. The metabolic syn- drome and endothelialdysfunction: common highway to type 2 diabetes and cardiovascular disease. Curr Diab Rep 2006; 6(4): 279-286.
  12. Lutsey PL, Steffen LM, Stevens J. Dietary intake and the development of the metabolic syn- drome: the Atherosclerosis Risk in Communi- ties Study. Circulation. 2008; 117(6): 754-761.
  13. Van Raalte DH, Brands M, Van der Zijl NJ et al. Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Diabetologia 2011; 54(8): 2103-2112.
  14. Baudrand R, Campino C, Carvajal CA et al. High sodium intake is associated with in- creased glucocorticoid produc